[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Messina\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":87},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,62],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100651831","liver-and-coagulation-disorders-in-cardiac-transthyretin-amyloidosis-100651831",false,"NCT07766135","Liver and Coagulation Disorders in Cardiac Transthyretin Amyloidosis","Liver and Coagulation Disorders in Cardiac Transthyretin Amyloidosis (ATTR-CA): New Horizons in Disease Staging and Follow-Up","LICA2025","Inclusion Criteria:\n\n* Written informed consent obtained prior to study participation.\n* Diagnosis of wild-type or hereditary transthyretin cardiac amyloidosis (ATTR-CA) according to current European recommendations.\n* Ability to comply with study procedures and follow-up visits.\n\nExclusion Criteria:\n\n* Age younger than 18 years.\n* Severe liver dysfunction due to causes other than amyloidosis.\n* Inability to comply with study procedures because of language barriers, cognitive impairment, or severe psychiatric disorders.\n* Comorbidities associated with life expectancy less than 12 months.\n* Active alcohol or substance abuse.\n* For coagulation analyses: congenital coagulation disorders, thrombotic disorders, active malignancy, or sepsis.\n* Pregnancy or breastfeeding.","ALL","18 Years",{"count":20,"type":21},70,"ESTIMATED","OBSERVATIONAL","Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive infiltrative cardiomyopathy caused by the deposition of misfolded transthyretin protein within the myocardium. Current disease staging and follow-up strategies mainly rely on cardiac biomarkers and renal function; however, the systemic nature of ATTR suggests that additional organ involvement may provide valuable prognostic information.\n\nThe purpose of this prospective observational study is to investigate liver dysfunction and coagulation abnormalities in patients with wild-type or hereditary ATTR-CA and to evaluate their potential role as novel markers of disease severity and progression. Patients with ATTR-CA will be compared with an age-matched control population with non-amyloid hypertrophic cardiomyopathy.\n\nClinical, laboratory, echocardiographic, hepatic ultrasound, liver stiffness, and coagulation parameters will be assessed at baseline and during follow-up. The study will also evaluate changes in these parameters after 6 and 12 months of treatment with tafamidis.\n\nThe results may improve the understanding of cardio-hepatic interactions in ATTR-CA and identify new tools for disease staging and longitudinal monitoring.",[25,26,27,28,29],"Transthyretin (TTR) Amyloid Cardiomyopathy","Cardiac Amyloidosis","Cardiomyopathies","Wild-Type Transthyretin Cardiac Amyloidosis","Hereditary Transthyretin Amyloidosis (ATTRv)",[31,32,26,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48],"ATTR","ATTR-CA","Transthyretin Amyloidosis","Tafamidis","Acoramidis","Liver Stiffness","Fibroscan","Liver Dysfunction","Hepatic Congestion","Coagulation Disorder","Hemostasis","Cardiohepatic Syndrome","Biomarkers","Disease Staging","Echocardiography","Heart Failure","Wild-Type ATTR","Hereditary ATTR","RECRUITING","2026-08-10",{"date":52,"type":53},"2026-08-14","ACTUAL",{"date":55,"type":53},"2026-01-30",{"date":57,"type":21},"2028-01",{"name":59,"class":60},"University of Messina","OTHER",1,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":4},"100599145","phase-4-short-term-dual-antiplatelet-therapy-with-early-transi-tion-to-low-dose-antiplatelet-monotherapy-using-ti-cagrelor-in-chronic-coronary-artery-disease-100599145","NCT07080684","Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease","Short-Term Dual Antiplatelet Therapy With Early Transition to Low-dose Antiplatelet Monotherapy Using ticagRelor in Chronic Coronary Artery Disease","STELAR","Inclusion Criteria:\n\n* Age ≥18 years at the time of informed consent.\n* Diagnosis of chronic coronary syndrome (CCS) according to ESC guidelines.\n* Undergoing successful PCI with implantation of one or more new-generation drug-eluting stents (DES).\n* Indication for dual antiplatelet therapy (DAPT) following PCI.\n* Willingness and ability to comply with all study procedures and follow-up assessments.\n* Signed informed consent prior to any study-specific procedure.\n* Creatinine clearance ≥30 mL\u002Fmin, calculated using the Cockcroft-Gault formula.\n* Life expectancy greater than 1 year in the investigator's judg-ment.\n* Hemodynamically stable at the time of randomization.\n* Acceptable bleeding risk profile: patients fulfilling ARC-HBR criteria may be included only if the treating physician deems a 6-month antiplatelet regimen to be safe.\n* No contraindications to study drugs, including aspirin, clopi-dogrel, or ticagrelor.\n\nExclusion Criteria:\n\n* Presentation with acute coronary syndrome (ACS), including STEMI, NSTEMI, or unstable angina within the previous 6 mon-ths.\n* Planned staged PCI or revascularization procedure within 6 months after index PCI.\n* Requirement for long-term oral anticoagulation therapy, such as for atrial fibrillation, mechanical heart valves, or venous thromboembolism.\n* History of major bleeding, including gastrointestinal or intra-cranial bleeding, within the past 6 months.\n* Severe hepatic impairment, active liver disease, or transamina-ses \\>3× upper limit of normal.\n* Known platelet disorder, coagulopathy, or thrombocytopenia (\\\u003C100,000\u002Fmm³).\n* Contraindication or hypersensitivity to aspirin, clopidogrel, or ticagrelor, or known drug interaction that precludes their use.\n* Ongoing active bleeding or high risk of bleeding that, in the opinion of the investigator, precludes DAPT.\n* Pregnancy or breastfeeding, or women of childbearing potential who are not using effective contraception.\n* Life expectancy \\\u003C1 year due to non-cardiovascular comorbidi-ties (e.g., cancer, advanced renal failure).\n* Participation in another interventional clinical trial that may interfere with the outcomes of this study.\n* Severe anemia (hemoglobin \\\u003C9 g\u002FdL) not corrected before ran-domization.\n* Inability or unwillingness to provide informed consent or ad-here to study follow-up.\n* Prior stroke with residual neurological deficit or history of di-sabling stroke (mRS ≥3).",{"count":71,"type":21},1000,"INTERVENTIONAL",[74],"PHASE4","This is a prospective, multicenter, randomized, open-label trial with blinded endpoint adjudication (PROBE design), comparing one-month dual antiplatelet therapy (DAPT) with low-dose ticagrelor (60 mg BID) followed by ticagrelor monotherapy to standard 6-month DAPT with aspirin and clopidogrel in patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI). The primary endpoint is a composite of cardiovascular death, all-cause death, myocardial infarction, disabling stroke, target lesion revascularization (TLR), and major bleeding. The study aims to evaluate whether the short DAPT strategy reduces ischemic events while maintaining bleeding safety.",[77],"Chronic Coronary Syndrome","NOT_YET_RECRUITING","2025-07-14",{"date":81,"type":53},"2025-07-23",{"date":83,"type":21},"2025-12-01",{"date":85,"type":21},"2027-09",{"name":59,"class":60},""]